ALKS News & Events

Sees FY26 adjusted EBITDA $370M-$410M. "In 2025, we generated total revenue of approximately $1.48 billion, strong profitability and cash flow. These results highlight the strength of our commercial portfolio and our continued focus on disciplined expense management," said Joshua Reed, CFO of Alkermes. "As reflected in our financial expectations, in 2026 we are poised to drive robust cash generation and profitability while rapidly advancing alixorexton in registrational studies and progressing the clinical program for additional orexin 2 receptor agonists in our portfolio. The completed acquisition of Avadel enhances our financial profile, broadens our commercial capabilities, and accelerates our entry into the sleep medicine market. This positions us well for the potential future launch of alixorexton. With a solid balance sheet, a diversified revenue base, and a focused capital allocation strategy, we believe Alkermes is well-positioned to deliver long-term growth and shareholder value."

Reports Q4 revenue $384.55M, consensus $381.49M. "Enabled by our strong operational and financial performance in 2025, Alkermes enters 2026 in a position of great strength, both financially and in terms of the opportunity to create value for shareholders through the development of important new medicines with significant market potential," said Richard Pops, CEO of Alkermes. "As we look ahead, our strategic priorities for the year are clear: drive strong performance across our portfolio of commercial products, including Lumryz following the recently completed acquisition of Avadel; for alixorexton, initiate phase 3 studies designed to support a best-in-class profile in narcolepsy and complete our phase 2 study in idiopathic hypersomnia; and advance additional orexin candidates into phase 2 development in attention-deficit hyperactivity disorder and fatigue associated with multiple sclerosis and Parkinson's disease. With strong momentum and a clear strategic vision, we are well positioned to deliver meaningful innovation and drive value in the years ahead."

Alkermes announced that Richard Pops will retire from his role as CEO, effective July 31. Alkermes' Board of Directors appointed Blair Jackson, Alkermes' current Executive Vice President, COO, as the company's next CEO, effective August 1. Jackson is also expected to join the Board at that time. Following the transition, Pops will continue to serve as Chairman of the Board and will act as an advisor to the company's executive team.